The window Sarasota has been waiting on is almost open.
Sarasota is one of the most concentrated longevity markets in the country. The median age in this county is north of fifty-five. The concierge medicine cluster along Tamiami Trail and out toward Lakewood Ranch has been quietly building age-management protocols around licensed bioidentical hormone work for almost two decades. What is changing now is that the federal regulatory frame around growth-hormone-axis peptides is finally moving, and the providers in this market who have been waiting on a clean legal lane are about to get one.
The short version: in 2023 the FDA placed several named peptides — including BPC-157, KPV, TB-500, MOTs-C, and others — into Category 2 of the 503A bulk substances list, which restricts but does not prohibit compounding. On April 16, 2026 a Federal Register notice reopened the nominations process. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review the science and vote on whether those compounds move into Category 1 (compoundable under 503A) or stay in Category 2. Whatever the committee decides, the providwrs in Florida who have been preparing for that meeting are about to be in a very different position than they were eighteen months ago.
Florida itself helped clear the runway. Senate Bill 1768, signed in 2023, explicitly preserved 503A compounding authority within the state and codified the prescriber-pharmacy relationship that this entire category depends on. That is one reason Sarasota's concierge endocrinology and longevity practices have been able to keep working with licensed compounding pharmacies through a period when other states tightened up. Find Peptide Clinics exists to make that legitimate, licensed lane easy to find — and to make the gray-market storefronts easy to avoid.